Tag Archive for: #Synaffix

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement Amsterdam, The Netherlands, 9 January 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with […]

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology

Amsterdam, The Netherlands, Basel, Switzerland and Ingelheim, Germany, (9 January 2025) — Boehringer Ingelheim and Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven […]

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Licensing agreement gives Elevation Oncology access to Synaffix’s ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix’s proprietary ADC development technologies AMSTERDAM, THE NETHERLANDS, 12 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its […]

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina’s next-generation sequencing (NGS) products AMSTERDAM, THE NETHERLANDS, 4 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and […]

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs BigHat’s artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated […]